source
- Vertex and AbCellera team up to develop next-generation T-cell engagers for autoimmune diseasesVertex Pharmaceuticals has entered a partnership with AbCellera to create next-generation T-cell engagers aimed at autoimmune diseases. AbCellera will receive an upfront payment of $28 million, wit…
- Caldera Therapeutics merges with Synlogic, secures $278M to advance inflammation drugCaldera Therapeutics, a startup founded seven months ago with $112.5 million of venture funding, announced a merger with Synlogic, a company that previously went public via a reverse merger. The a…